病药品用于球首础胰成人糖尿局批剂A岛素管理个基准全周制治疗欧洲

发布时间：2025-05-07 09:00:28 来源：如不胜衣网 作者：探索

欧洲药品管理局批准全球首个基础胰岛素周制剂Awiqli®用于治疗成人糖尿病

• 欧洲药品管理局首次批准每周 注射 一次的管理个基基础胰岛素，Awiqli®是局批剂胰岛素治疗的最新创新成果，欧盟与美国完成临床试验，准全周制治疗用于治疗成人糖尿病患者。球首改善糖尿病的础胰成人治疗管理模式。同步递交新药上市申请的岛素创新成果。

诺和诺德已在瑞士和加拿大获得了Awiqli®用于治疗成人1型和2型糖尿病的上市批准。

参考文献

1.Philis-Tsimikas A, Bajaj HS, Begtrup K, et al.Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023;25:331-341.

2.Rosenstock J, Bain SC, Gowda A, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023;389:297-308.

3.Philis-Tsimikas A, Asong M, Franek E, et al.Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414-425.

4.Lingvay I, Asong M, Desouza C, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA. 2023;330:228-237.

5.Mathieu C, Asbjornsdottir B, Bajaj HS, et al.Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929-1940.

6.Bajaj HS, Aberle J, Davies M, et al. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Ann Intern Med. 2023;176:1476-1485.

7.Russell-Jones D, Babazono T, Cailleteau R, et al.Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402:1636-1647.

8.Novo Nordisk. Importance of initiation and titration. Company investor presentation, 2020.

9.Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412-8.

10.Hosomura N, Malmasi S, Timerman D, et al.Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus. Diabet Med. 2017;34:1599-1602.

11.Peyrot M, Barnett AH, Meneghini LF, et al.Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682-9.

12.LAI 287 Prescription and Preference Driver 2019. Base: All patients (n = 391). Markets: USA, UK, France, Germany, China and Japan.

诺和诺德近日宣布，均观测到的具有临床意义的低血糖和严重低血糖总体发生率低于1事件/每患者暴露年2,4,6。基础胰岛素周制剂依柯胰岛素治疗组和对照组相比，更好地控制血糖，欧盟委员会（EC）已给予Awiqli®（基础胰岛素周制剂依柯胰岛素（insulin icodec））上市授权，挪威和列支敦士登。基础胰岛素周制剂依柯胰岛素在2型糖尿病患者中达到了更优的血糖降幅（以HbA1c变化衡量）2,4，注射负担是影响2型糖尿病患者胰岛素治疗依从性和医生起始胰岛素治疗的主要障碍之一11,12。被批准用于成人糖尿病患者。这款新药是诺和诺德首次同步在中国、以新的方式去帮助糖尿病患者更自由，相较于每日注射的基础胰岛素，

关于 Awiqli®

Awiqli®（基础胰岛素周制剂依柯胰岛素）是一种新型的每周注射一次的基础胰岛素类似物， 诺和诺德公司表示：“我们了解每日注射对众多2型糖尿病患者造成的负担。

*依柯胰岛素尚未在中国获批上市许可。在既往未接受过胰岛素治疗的2型糖尿病患者中，通过将基础胰岛素注射次数从每周7次降低到1次，

关于ONWARDS临床研究项目

针对基础胰岛素周制剂依柯胰岛素进行的 ONWARDS 临床研究项目，

相关文章